Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.
Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG; for the Teduglutide Study GroupList of participating investigators and centers: Ertan, Atilla (Houston, TX); Fang, John (University of Utah), Wo, John (University of Louisville); Bassan, Issac (North Miami Beach, FL); Goff, John (Lakewood, CO); Lashner, Brett (Cleveland Clinic); Katz, Seymour (Great Neck, NY); Prakash, Jay (Atlanta, GA); Hanauer, Stephen (University of Chicago); Krone, Charles (Tucson, AZ); Lebovitz, Paul (Pittsburgh); Buchman, Alan (Northwestern University, Chicago); Abou‐Assi, Sounen (McGuire VAMC, Richmond, VA); Ziegler, Thomas (Emory University, Atlanta); Hamilton, John (Madison, WI); Saucego, Juno (Washington DC); Loewe, Charles (Sarasota, FL); Oranglo, Guy (Atlanta, GA); Anderson, Frank (Vancouver, BC); Bernstein, Charles (Univ of Manitoba, Winnepeg); Cohen Lawrence (Toronto, ON); Leddin, Desmond (Halifax, NS); Weiss, L Michael (Clearwater, FL); Zwick, Andrew (Boca Raton, FL); Kornbluth, Asher (Mt. Sinai Hospital, New York); Petrunia, Dennis (Victoria, BC); Dhana, Sonny (Brandon, MD); Barish, Charles (Raleigh, NC); Chiba, Naoki (Guelph, ON); Liebermann, Thomas (Austin, TX); Hogin James (Oklahoma, OK); Cortese, Florian (Butte, MT)..
Inflamm Bowel Dis. 2009 Oct 9. [Epub ahead of print]PMID: 19821509 [PubMed - as supplied by publisher]Related articles